Payment overview · 2025
General Payments
$42.57
3 reported records · 1 companies
Healthcare provider profile · identity verified
Sudhir Kumar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FORREST CITY, AR · NPI 1275509069
Verified facts
What the public records show
CMS Open Payments records show Sudhir Kumar, M.D. received $42.57 in general payments during 2025 across 3 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.57 | 100.0% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $42.57 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.57 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 130 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
130 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 960 | 239 |
| Amlodipine Besylate | Amlodipine Besylate | 720 | 161 |
| Losartan Potassium | Losartan Potassium | 513 | 134 |
| Pantoprazole Sodium | Pantoprazole Sodium | 511 | 139 |
| Furosemide | Furosemide | 484 | 128 |
| Potassium Chloride | Potassium Chloride | 437 | 99 |
| Omeprazole | Omeprazole | 406 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 357 | 87 |
| Gabapentin | Gabapentin | 339 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 332 | 76 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 316 | 75 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 303 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 294 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 290 | 78 |
| Atenolol | Atenolol | 287 | 68 |
| Simvastatin | Simvastatin | 285 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 283 | 63 |
| Lisinopril | Lisinopril | 281 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 262 | 59 |
| Glipizide Er | Glipizide | 261 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 260 | 112 |
| Nifedipine Er | Nifedipine | 242 | 53 |
| Allopurinol | Allopurinol | 241 | 60 |
| Prednisone | Prednisone | 226 | 141 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 56 |
| Terazosin Hcl | Terazosin Hcl | 214 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 77 |
| Mounjaro | Tirzepatide | 187 | 24 |
| Carvedilol | Carvedilol | 181 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 179 | 44 |
| Metformin Hcl | Metformin Hcl | 179 | 47 |
| Alprazolam | Alprazolam | 178 | 36 |
| Clonazepam | Clonazepam | 177 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 172 | 38 |
| Ozempic | Semaglutide | 172 | 24 |
| Torsemide | Torsemide | 163 | 41 |
| Tramadol Hcl | Tramadol Hcl | 163 | 61 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 154 | 38 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 150 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 150 | 33 |
| Megestrol Acetate | Megestrol Acetate | 145 | 38 |
| Linzess | Linaclotide | 138 | 36 |
| Labetalol Hcl | Labetalol Hcl | 134 | 37 |
| Eliquis | Apixaban | 130 | 38 |
| Levetiracetam | Levetiracetam | 130 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 130 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 128 | 80 |
| Clonidine | Clonidine | 125 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 27 |
| Xarelto | Rivaroxaban | 118 | 22 |
| Farxiga | Dapagliflozin Propanediol | 117 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 29 |
| Pregabalin | Pregabalin | 114 | 34 |
| Levofloxacin | Levofloxacin | 110 | 91 |
| Spironolactone | Spironolactone | 108 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 30 |
| Lorazepam | Lorazepam | 100 | 24 |
| Celecoxib | Celecoxib | 97 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 30 |
| Temazepam | Temazepam | 91 | 24 |
| Jardiance | Empagliflozin | 90 | 19 |
| Clonidine Hcl | Clonidine Hcl | 89 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 89 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 31 |
| Azithromycin | Azithromycin | 85 | 68 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 22 |
| Finasteride | Finasteride | 80 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 73 | 21 |
| Meloxicam | Meloxicam | 72 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 22 |
| Methotrexate | Methotrexate Sodium | 68 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 12 |
| Risperidone | Risperidone | 68 | 11 |
| Montelukast Sodium | Montelukast Sodium | 64 | suppressed |
| Januvia | Sitagliptin Phosphate | 60 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 15 |
| Carbamazepine | Carbamazepine | 59 | suppressed |
| Colchicine | Colchicine | 59 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | suppressed |
| Estradiol | Estradiol | 58 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 57 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 57 | 21 |
| Alendronate Sodium | Alendronate Sodium | 56 | 13 |
| Glipizide | Glipizide | 55 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 54 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 14 |
| Sucralfate | Sucralfate | 51 | 16 |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 50 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 49 | 34 |
| Folic Acid | Folic Acid | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Gemfibrozil | Gemfibrozil | 45 | 13 |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 11 |
| Ramipril | Ramipril | 44 | 11 |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 44 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 11 |
| Baclofen | Baclofen | 42 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 27 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | 11 |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 24 |
| Metformin Hcl Er | Metformin Hcl | 36 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 35 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Cilostazol | Cilostazol | 34 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 32 | 32 |
| Fluconazole | Fluconazole | 31 | 21 |
| Cephalexin | Cephalexin | 30 | 26 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 29 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 29 | 22 |
| Famotidine | Famotidine | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 26 | 21 |
| Cefuroxime | Cefuroxime Axetil | 25 | 22 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Diphtheria-Tetanus Toxoids-Ped | Tetanus,diphtheria Toxd Ped/Pf | 23 | 23 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | 11 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Zonisamide | Zonisamide | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fluorouracil | Fluorouracil | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | 13 |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | 11 |
| Novolog | Insulin Aspart | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $42.57 · 3 records | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error